After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Avidity Biosciences Inc. (RNA) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $24.34. The Avidity Biosciences Inc. has recorded 502,979 volume in the after hours trading session.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Stocks Info
RNA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $24.34 and fluctuated between $25.38 as its day high and $22.81 as its day low. The current market capitalization of Avidity Biosciences Inc. is $1.68B. A total of 1.0 million shares were traded on the day, compared to an average of 2.02M shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, RNA has seen 5 BUY and 2 SELL insider trades, representing the acquisition of 136,500 and the disposition of 50,000 shares. Over the last 12 months, there were 12 BUYs and 8 SELLs from insiders. Insiders purchased 266,500 shares during that period but sold 180,000.
In the most recent transaction, LEVIN ARTHUR A sold 10,000 shares of RNA for 23.66 per share on Feb 14. After the transaction, the Chief Scientific Officer now owns 19,330 company shares. In a previous transaction on Feb 03, Boyce Sarah sold 3,221 shares at 24.26 per share. RNA shares that President and CEO owns now total 53,352.
Among the insiders who sold shares, Boyce Sarah disposed of 45,879 shares on Feb 02 at a per-share price of $24.36. This resulted in the President and CEO holding 53,352 shares of RNA after the transaction. In another insider transaction, Boyce Sarah sold 900 shares at $24.27 per share on Feb 01. Company shares held by the President and CEO now total 53,352.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for RNA in the last 3 months, the mean price target is $43.29 with high estimates of $71.00 and low estimates of $27.00. In terms of 52-week highs and lows, RNA has a high of $25.74 and a low of $9.83.
As of this writing, RNA has an earnings estimate of -$0.89 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.75 per share and a lower estimate of -$1.07. The company reported an EPS of -$0.92 in the last quarter, which was -22.70% lower than expectations of -$0.75.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNA is Overweight with a score of 4.83. A total of 8 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.
